<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>chemoresistance &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/chemoresistance/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 19 Jan 2026 04:51:07 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>chemoresistance &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>M6A Modification Boosts Osteosarcoma Progression via Ca2+ Signaling</title>
		<link>https://bioengineer.org/m6a-modification-boosts-osteosarcoma-progression-via-ca2-signaling/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 19 Jan 2026 04:50:40 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Calcium signaling]]></category>
		<category><![CDATA[chemoresistance]]></category>
		<category><![CDATA[m6A modification]]></category>
		<category><![CDATA[METTL3]]></category>
		<category><![CDATA[Osteosarcoma]]></category>
		<category><![CDATA[Osteosarcoma progression]]></category>
		<category><![CDATA[WNT signaling **Kısa Açıklama:** Bu etiketler makalenin temel odağını kapsar: 1. **METTL3:** Ana araştırılan enzim/methyltransferase. 2. **m6A modification:** Çalışmanın temel moleküler mekanizması. 3]]></category>
		<guid isPermaLink="false">https://bioengineer.org/m6a-modification-boosts-osteosarcoma-progression-via-ca2-signaling/</guid>

					<description><![CDATA[Recent research has made significant strides in unveiling the molecular underpinnings of osteosarcoma, a challenging and aggressive bone malignancy predominantly affecting children and adolescents. A pivotal study led by Chen et al. investigates the role of METTL3, a pivotal methyltransferase, in the dynamic landscape of m^6A modification, particularly its influence on the CACNA1E gene. This [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318131</post-id>	</item>
		<item>
		<title>SLC Transporters: Targeting Ovarian Cancer Treatment Innovations</title>
		<link>https://bioengineer.org/slc-transporters-targeting-ovarian-cancer-treatment-innovations/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 14 Jan 2026 01:39:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[chemoresistance]]></category>
		<category><![CDATA[İşte içerikle en uyumlu 5 etiket]]></category>
		<category><![CDATA[ovarian cancer treatment]]></category>
		<category><![CDATA[Precision medicine** **Kısa açıklama:** * **SLC transporters:** Makalenin temel konusu ve anahtar molekülleri. * **Ovarian cancer treatment:** Araştırmanın amacı]]></category>
		<category><![CDATA[therapeutic targets]]></category>
		<category><![CDATA[virgülle ayrılmış olarak: **SLC transporters]]></category>
		<guid isPermaLink="false">https://bioengineer.org/slc-transporters-targeting-ovarian-cancer-treatment-innovations/</guid>

					<description><![CDATA[In a groundbreaking exploration of the biochemical landscape of ovarian serous cystadenocarcinoma, researchers have put a spotlight on the Solute Carrier (SLC) Transporter Superfamily, unveiling their potential as therapeutic targets. This family of transporters is critically involved in the cellular uptake and efflux of various substrates, making them pivotal players in numerous physiological and pathological [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">316691</post-id>	</item>
		<item>
		<title>DDX6 Phase Separation Drives Chemoresistance, Metabolic Flexibility</title>
		<link>https://bioengineer.org/ddx6-phase-separation-drives-chemoresistance-metabolic-flexibility/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 03 Dec 2025 01:02:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[chemoresistance]]></category>
		<category><![CDATA[DDX6]]></category>
		<category><![CDATA[metabolic plasticity]]></category>
		<category><![CDATA[molecular condensates]]></category>
		<category><![CDATA[phase separation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ddx6-phase-separation-drives-chemoresistance-metabolic-flexibility/</guid>

					<description><![CDATA[In a groundbreaking study poised to redefine our understanding of cancer biology and therapeutic resistance, researchers have unveiled the intricate role of the RNA helicase protein DDX6 in facilitating metabolic plasticity and chemoresistance through a biophysical process known as phase separation. This discovery is not only transforming molecular oncology but also opening new avenues for [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">304627</post-id>	</item>
	</channel>
</rss>
